Immupharma PLC Dr. S Muller, founder of Lupuzor presentation.
April 23 2014 - 2:00AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
23 April 2014
FOR IMMEDIATE RELEASE RNS REACH 23 APRIL 2014
Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka
University, Japan
ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
announced that Dr. Sylviane Muller was recently invited by the
Immunology Frontier Research Center of Osaka University, an
internationally renowned research center in the field of
immunology, to hold a seminar on the approach of Lupuzor for
treating lupus patients. The details of her abstract have now been
released.
Dr. Sylviane Muller, Research Director at CNRS, Strasbourg,
France is the key inventor of Lupuzor. Her abstract was titled
"Chaperone-mediated autophagy as a target of therapeutic P140
peptide used in lupus". Her presentation focused partly on the on
the highly competitive and efficacious mode of mechanism of
Lupuzor(TM) (also known scientifically as P140), ImmuPharma's
potential blockbuster drug for Lupus, a chronic autoimmune disease.
Lupuzor(TM) has received Special Protocol Assessment and Fast Track
Designation from the FDA for a Phase III trial.
Sylviane Muller's Abstract : Summary
"In the pipeline of molecules with a potential for treating
lupus patients, the P140 peptide holds a lot of promise. P140 is a
21-mer linear peptide (sequence 131-151) derived from the
spliceosomal small nuclear ribonucleoprotein U1-70K. It contains a
phosphoserine residue at position 140. In a multicenter,
randomized, placebo-controlled phase IIb study, P140/Lupuzor was
safe and met its primary efficacy end points in lupus patients
(Zimmer et al., ARD 2013). These results confirm data generated in
MRL/lpr lupus-prone mice in which the preclinical studies were
conducted (Monneaux et al., EJI 2003; Schall et al., J Autoimmunity
2012). In this setting, as in human, P140 was shown to behave as an
immunomodulator and not as an immunosuppressant. In a step further,
our studies demonstrated that the P140 peptide mechanism of action
does involve autophagy processes. In a lupus context in which
macroautophagy is affected (Gros et al., 2012), P140 readily binds
HSPA8/HSC70 chaperone proteins (Page et al., PLoS ONE 2009) and
reduces autophagic flux in MRL/lpr B cells (Page et al., ARD 2011).
We recently showed that a selective form of autophagy,
chaperone-mediated autophagy (CMA), is a key target of P140. By
interfering with this particular pathway, P140 peptide may affect
the endogenous (auto)antigen processing and the peptide loading to
MHCII molecules, and as a consequence, induces a lower activation
of autoreactive T and B cells, and a reduction of autoantibodies
secreted by plasma cells. Our recent results shed light on
mechanisms by which P140 can modulate lupus disease and by which it
may operate in humans affected by this disorder that affect more
than 5 million individuals in the world".
For further information please contact:
ImmuPharma PLC (www.immupharma.com)
Dimitri Dimitriou, Chief Executive
Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Lisa Baderoon, Head of Investor
Relations +44 7721 413 496
+44 (0)20 7886
Panmure Gordon & Co 2500
Hugh Morgan, Fred Walsh
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has received the approval
from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. Most recent news confirmed
a five year GBP50m funding facility from Darwin Strategic and the
establishment of a Scientific Advisory Board to provide scientific
advice and support for Lupuzor's pivotal phase III programme.
ImmuPharma was founded and is led by a commercially focused Board
and management team with extensive experience.
www.immupharma.com
Dr. Sylviane Muller, Research Director at CNRS & Co-founder
of ImmuPharma France
Sylviane Muller is Professor at the Institute for Advanced Study
of the University of Strasbourg (USIAS), holder of the chair of
immunology and therapeutic chemistry, Distinguished class Research
Director and head of the 'Immunologie et chimie thérapeutiques'
unit of the "Centre National de la Recherche Scientifique" (CNRS),
the largest fundamental research organization in Europe. She
obtained her PhD at the University of Strasbourg. For two years,
she was a post-doctoral fellow in Freiburg (Germany) at the
Max-Planck Institute for Immunobiology. Her field of expertise
covers autoimmunity, immuno-peptides and synthetic vaccines. She
has made 23 patented discoveries and is widely published (330
publications and reviews/chapters). She was also a founder of
Neosystem, now Polypeptide-France, a leading peptide development
and manufacturing company. She is the key inventor of ImmuPharma's
Lupus lead drug candidate Lupuzor and has been working in this
field for more than ten years.
Osaka University Immunology Frontier Research Center (IFReC)
The IFReC was launched on October 1st, 2007 as part of the World
Premier International (WPI) Research Center Program initiated by
the Ministry of Education, Culture, Sports, Science and Technology
(MEXT).
Since then the IFReC has engaged in high-level research that is
expected to make it an internationally renowned research center in
the field of immunology.
Immunology explores the mechanisms that protect the body against
various pathogens such as bacteria and viruses. Because the immune
system is essential for eliminating infectious pathogens from the
body, its malfunction gives rise to various immune disorders
including allergies, cancers, autoimmune diseases, and allograft
rejection during transplantation.
The scientific aim of IFReC is to contribute to a more
comprehensive understanding of the dynamics of the immune system by
employing not only traditional immunology experiments, but also a
variety of imaging and bioinformatics technologies. In order to
accomplish this goal, IFReC has recruited a diverse team of imaging
and informatics scientists. These efforts will enable immunologists
to directly track the dynamic behavior of immune cells and their
cell-to-cell networks in order to clarify how immune cells respond
to pathogens and cancers in vivo.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAITMRTMBBTBRI
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
